Peter A. Nigrovic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter A. Nigrovic has a total of 952 co-authors. Here are the top co-authors by number of shared publications:
- Pui Y. Lee
Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
16 shared publications - Lauren A. Henderson
Boston Children's Hospital Harvard Medical School Boston Massachusetts
14 shared publications - Margaret H. Chang
Boston Children's Hospital Boston Massachusetts
11 shared publications Alexandra Wactor
Department of Pediatrics, Division of Immunology, Boston Children’s Hospital, Harvard Medical School; Boston, MA, USA
10 shared publicationsMarta Martínez-Bonet
Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
10 shared publications- Ricardo Grieshaber-Bouyer
Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
10 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Still the one: Transcriptional control across leukopoiesis by SPI1/PU.1
The transcription factor (TF) SPI1 (historically called PU.1) is a critical pioneer TF and regulator of hematopoiesis. It exerts exquisitely dose-dependent and stage-specific control over lymphoid, myeloid, and central nervous system–resident lineages. Structurally characterized by an intrinsically disordered N-terminal transactivation region and a highly conserved C-terminal DNA-binding E26 transformation–specific domain, SPI1 can operate alone as a monomer, via homodimerization, through epigenetic interactions, and in context-dependent transcriptional partnerships. While early animal models established its essentiality for leukopoiesis, modern human genomics has unveiled direct links between altered SPI1 function and disease. Heterozygous loss-of-function germline variants cause PU.1-mediated agammaglobulinemia, whereas somatic mutations and/or regulatory alterations can drive hematologic malignancies. Dysregulated SPI1 activity is also implicated in autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, and neurodegenerative disorders. This review reconciles foundational murine paradigms with emerging human translational data, highlights current therapeutic landscapes, and projects how single-cell multi-omics and advanced gene editing may shape future directions in the SPI1 biomedical field.
- 12 November 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 3 (1)
Open AccessStill the one: Transcriptional control across leukopoiesis by SPI1/PU.1
The transcription factor (TF) SPI1 (historically called PU.1) is a critical pioneer TF and regulator of hematopoiesis. It exerts exquisitely dose-dependent and stage-specific control over lymphoid, myeloid, and central nervous system–resident lineages. Structurally characterized by an intrinsically disordered N-terminal transactivation region and a highly conserved C-terminal DNA-binding E26 transformation–specific domain, SPI1 can operate alone as a monomer, via homodimerization, through epigenetic interactions, and in context-dependent transcriptional partnerships. While early animal models established its essentiality for leukopoiesis, modern human genomics has unveiled direct links between altered SPI1 function and disease. Heterozygous loss-of-function germline variants cause PU.1-mediated agammaglobulinemia, whereas somatic mutations and/or regulatory alterations can drive hematologic malignancies. Dysregulated SPI1 activity is also implicated in autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus, and neurodegenerative disorders. This review reconciles foundational murine paradigms with emerging human translational data, highlights current therapeutic landscapes, and projects how single-cell multi-omics and advanced gene editing may shape future directions in the SPI1 biomedical field.
- Open Access
- 23 October 2026
- Published by Springer Nature in Nature Communications
Multi-omics profiling of primary human B cells activated via distinct stimuli
B cells are central for immunity and immune-mediated diseases (IMD), but how distinct signaling pathways drive diverse activation responses over time is not comprehensively understood. Here, we obtain peripheral blood B cells from 27 female healthy donors for in vitro stimulation, profiling the response at multiple time points using RNA-seq, single-cell RNA-seq with surface protein markers (CITE-seq), and ATAC-seq. Using diverse stimuli including activation of the B cell receptor (BCR), Toll-like receptor 7 (TLR7), TLR9, CD40, and differentiation into double negative 2 (DN2) IgD – CD27 – CD11c + CD21 – B cells, our analyses uncover activation-dependent B cell states, stimulation-specific transcription factors and regulatory regions, the dynamic response of IMD-associated gene expression, and specific open chromatin regions associated with IMD genetic risk. Furthermore, we also identify a lupus risk variant in an enhancer regulating TNFSF4 expression. The analysis data can be accessed via an interactive browser: https://mgalab.shinyapps.io/bcellactivation . Our findings underscore how profiling the full breadth of B cell activation pathways may be important for understanding B cell biology in health and disease.
- 23 October 2026
- Published by Springer Nature in Nature Communications
Open AccessMulti-omics profiling of primary human B cells activated via distinct stimuli
B cells are central for immunity and immune-mediated diseases (IMD), but how distinct signaling pathways drive diverse activation responses over time is not comprehensively understood. Here, we obtain peripheral blood B cells from 27 female healthy donors for in vitro stimulation, profiling the response at multiple time points using RNA-seq, single-cell RNA-seq with surface protein markers (CITE-seq), and ATAC-seq. Using diverse stimuli including activation of the B cell receptor (BCR), Toll-like receptor 7 (TLR7), TLR9, CD40, and differentiation into double negative 2 (DN2) IgD – CD27 – CD11c + CD21 – B cells, our analyses uncover activation-dependent B cell states, stimulation-specific transcription factors and regulatory regions, the dynamic response of IMD-associated gene expression, and specific open chromatin regions associated with IMD genetic risk. Furthermore, we also identify a lupus risk variant in an enhancer regulating TNFSF4 expression. The analysis data can be accessed via an interactive browser: https://mgalab.shinyapps.io/bcellactivation . Our findings underscore how profiling the full breadth of B cell activation pathways may be important for understanding B cell biology in health and disease.
- Open Access
Identification and evaluation of 41 risk loci for juvenile idiopathic arthritis informs precision medicine: mechanistic implications of DNA topology and an HLA-A*02:01-ERAP2 interaction
Juvenile idiopathic arthritis (JIA), the most common class of pediatric rheumatic diseases, can lead to joint damage and extra-articular features including uveitis. Early treatment can improve functional outcomes; but many patients do not respond to first-line treatments. We present a JIA Immunochip-based association analysis of rheumatoid factor-negative polyarticular JIA and oligoarticular JIA. This study spans 3,939 cases and 14,412 controls, including 1,123 cases and 1,356 controls not previously analyzed. We identify 41 (14 novel) JIA risk regions and report a JIA polygenic risk score that also associates with age of onset. Functional mechanisms presented include: a novel interaction between HLA-A*02:01 and ERAP2 , cluster-based approach for functional amino acid discovery within HLA-DRB1, and sequence-dependent DNA topology for variant prioritization. We present a comprehensive list of curated gene-drug/small molecule interactions for clinically focused studies. These findings provide a deepened understanding of the genetics of JIA and potential mechanisms to inform precision medicine.
Open AccessIdentification and evaluation of 41 risk loci for juvenile idiopathic arthritis informs precision medicine: mechanistic implications of DNA topology and an HLA-A*02:01-ERAP2 interaction
Juvenile idiopathic arthritis (JIA), the most common class of pediatric rheumatic diseases, can lead to joint damage and extra-articular features including uveitis. Early treatment can improve functional outcomes; but many patients do not respond to first-line treatments. We present a JIA Immunochip-based association analysis of rheumatoid factor-negative polyarticular JIA and oligoarticular JIA. This study spans 3,939 cases and 14,412 controls, including 1,123 cases and 1,356 controls not previously analyzed. We identify 41 (14 novel) JIA risk regions and report a JIA polygenic risk score that also associates with age of onset. Functional mechanisms presented include: a novel interaction between HLA-A*02:01 and ERAP2 , cluster-based approach for functional amino acid discovery within HLA-DRB1, and sequence-dependent DNA topology for variant prioritization. We present a comprehensive list of curated gene-drug/small molecule interactions for clinically focused studies. These findings provide a deepened understanding of the genetics of JIA and potential mechanisms to inform precision medicine.
- Open Access
Megakaryocyte emperipolesis arms neutrophils via intracellular provisioning
Neutrophils are phenotypically heterogenous cells that mediate host defense and tissue homeostasis. Here, we identify emperipolesis – the evolutionarily conserved process by which neutrophils pass through megakaryocytes – as a phenotypically transformative route of egress from bone marrow. By intravital microscopy and 3-D histology, we show that the rapid form emperipolesis is markedly enhanced under inflammatory conditions. Neutrophils exit from megakaryocytes directly to the blood, acquiring exosomes enriched in proteins related to metabolism, migration, and immune function. This transfer induces a distinct neutrophil phenotype characterized by enhanced glycolysis, oxidative phosphorylation, cytokine release, and longevity. Correspondingly, emperipolesis-educated neutrophils display accelerated migration in vitro and in vivo . Disrupting emperipolesis does not alter circulating neutrophil abundance but impairs neutrophil infiltration into inflamed tissues, including Pseudomonas aeruginosa -infected lung. These findings establish emperipolesis as a mechanism by which megakaryocytes amplify neutrophil-mediated immunity.
Open AccessMegakaryocyte emperipolesis arms neutrophils via intracellular provisioning
Neutrophils are phenotypically heterogenous cells that mediate host defense and tissue homeostasis. Here, we identify emperipolesis – the evolutionarily conserved process by which neutrophils pass through megakaryocytes – as a phenotypically transformative route of egress from bone marrow. By intravital microscopy and 3-D histology, we show that the rapid form emperipolesis is markedly enhanced under inflammatory conditions. Neutrophils exit from megakaryocytes directly to the blood, acquiring exosomes enriched in proteins related to metabolism, migration, and immune function. This transfer induces a distinct neutrophil phenotype characterized by enhanced glycolysis, oxidative phosphorylation, cytokine release, and longevity. Correspondingly, emperipolesis-educated neutrophils display accelerated migration in vitro and in vivo . Disrupting emperipolesis does not alter circulating neutrophil abundance but impairs neutrophil infiltration into inflamed tissues, including Pseudomonas aeruginosa -infected lung. These findings establish emperipolesis as a mechanism by which megakaryocytes amplify neutrophil-mediated immunity.
- Open Access
- 22 May 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (6) , 1130-1144
A glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines
The activation of pattern recognition receptors (PRRs) orchestrates inflammation and regulates adaptive immunity. To test whether tuning inflammation through PRR stimulation enhanced the efficacy of mRNA vaccines, we combined an mRNA-based vaccine generated against the ancestral spike protein of SARS-CoV-2 with mannadjuvant, a formulation of fungal mannan and aluminum hydroxide targeting the PRR dectin-2. In mice and non-human primates, mannadjuvant increased the magnitude and durability of the response elicited by the mRNA-based vaccine, and it also led to the induction of neutralizing antibodies directed against variants of concern with a high escape capacity, overcoming antigenic imprinting. Mechanistically, prolonged type I interferon (IFN) production and potentiated interleukin-1 (IL-1) signaling locally within the draining lymph node in mice or in human cells were necessary and sufficient to exert the effect of mannadjuvant. Our data indicate that antifungal PRRs can be harnessed to create more potent and durable mRNA-based vaccines.
- 22 May 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (6) , 1130-1144
Open AccessA glycan-based adjuvant expands the breadth and duration of protection of mRNA-based vaccines
The activation of pattern recognition receptors (PRRs) orchestrates inflammation and regulates adaptive immunity. To test whether tuning inflammation through PRR stimulation enhanced the efficacy of mRNA vaccines, we combined an mRNA-based vaccine generated against the ancestral spike protein of SARS-CoV-2 with mannadjuvant, a formulation of fungal mannan and aluminum hydroxide targeting the PRR dectin-2. In mice and non-human primates, mannadjuvant increased the magnitude and durability of the response elicited by the mRNA-based vaccine, and it also led to the induction of neutralizing antibodies directed against variants of concern with a high escape capacity, overcoming antigenic imprinting. Mechanistically, prolonged type I interferon (IFN) production and potentiated interleukin-1 (IL-1) signaling locally within the draining lymph node in mice or in human cells were necessary and sufficient to exert the effect of mannadjuvant. Our data indicate that antifungal PRRs can be harnessed to create more potent and durable mRNA-based vaccines.
- Open Access
- 20 April 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (2)
Precision editing of cyclophilin A generates cyclosporine- and voclosporin-resistant cellular therapies
- 20 April 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (2)
Open AccessPrecision editing of cyclophilin A generates cyclosporine- and voclosporin-resistant cellular therapies
- Open Access
- 17 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
TAK1 inhibition restores p53 expression and suppresses inflammation and hyperplasia in juvenile idiopathic arthritis synovial fibroblasts
Objectives: This study investigated the role of TGF-β-activated kinase 1 (TAK1) in synovial inflammation and hyperplasia in JIA synovial fibroblasts (JIASFs). Methods: Patient-derived JIASFs were treated with TNF-α, IL-1β, and IFN-γ with and without various TAK1 inhibitors. ELISA, Western blotting, RNA sequencing, cell proliferation, and immunofluorescence were performed to study protein expression and JIASF functions. In vivo efficacy of TAK1 inhibitors was tested in a collagen antibody-induced arthritis (CAIA) model in IFN-γ knockout mice. Results: JIASFs exhibited elevated TAK1 and reduced basal p53 expression compared with human foreskin fibroblasts. IL-1β-activated TAK1 suppressed p53, promoting inflammatory marker expression. TAK1 inhibitors 5Z-7-oxozeaenol (IC50: 22.8 nM) and NG-25 (IC50: 492 nM) effectively blocked IL-1β-induced TAK1 activation, reducing inflammation. Notably, 5Z selectively restored IL-1β-suppressed p53 and p21 levels and demonstrated anti-proliferative effects via cell proliferation assays and reduced PCNA expression. Among tested inhibitors, 5Z was most effective in suppressing the combined pro-inflammatory effects of IL-1β, TNF-α, and IFN-γ, reducing COX-2, VCAM-1, cadherin-1, IL-6, IL-8, CXCL5, and MMP-3 expression by 80%. Furthermore, 5Z restored p53 expression more efficiently than MAPK or NF-κB pathway inhibitors. RNA-sequencing confirmed its anti-inflammatory and anti-proliferative properties in JIASFs. In vivo, daily intraperitoneal administration of 5Z (2 mg/kg) from day 3 significantly ameliorated collagen antibody-induced arthritis (CAIA) in IFN-γ knockout mice, highlighting its therapeutic potential. Conclusion: TAK1 inhibition restores p53 functions in JIASFs and downregulates synovial inflammation, which warrants further studies that target TAK1 to treat JIA.
- 17 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Open AccessTAK1 inhibition restores p53 expression and suppresses inflammation and hyperplasia in juvenile idiopathic arthritis synovial fibroblasts
Objectives: This study investigated the role of TGF-β-activated kinase 1 (TAK1) in synovial inflammation and hyperplasia in JIA synovial fibroblasts (JIASFs). Methods: Patient-derived JIASFs were treated with TNF-α, IL-1β, and IFN-γ with and without various TAK1 inhibitors. ELISA, Western blotting, RNA sequencing, cell proliferation, and immunofluorescence were performed to study protein expression and JIASF functions. In vivo efficacy of TAK1 inhibitors was tested in a collagen antibody-induced arthritis (CAIA) model in IFN-γ knockout mice. Results: JIASFs exhibited elevated TAK1 and reduced basal p53 expression compared with human foreskin fibroblasts. IL-1β-activated TAK1 suppressed p53, promoting inflammatory marker expression. TAK1 inhibitors 5Z-7-oxozeaenol (IC50: 22.8 nM) and NG-25 (IC50: 492 nM) effectively blocked IL-1β-induced TAK1 activation, reducing inflammation. Notably, 5Z selectively restored IL-1β-suppressed p53 and p21 levels and demonstrated anti-proliferative effects via cell proliferation assays and reduced PCNA expression. Among tested inhibitors, 5Z was most effective in suppressing the combined pro-inflammatory effects of IL-1β, TNF-α, and IFN-γ, reducing COX-2, VCAM-1, cadherin-1, IL-6, IL-8, CXCL5, and MMP-3 expression by 80%. Furthermore, 5Z restored p53 expression more efficiently than MAPK or NF-κB pathway inhibitors. RNA-sequencing confirmed its anti-inflammatory and anti-proliferative properties in JIASFs. In vivo, daily intraperitoneal administration of 5Z (2 mg/kg) from day 3 significantly ameliorated collagen antibody-induced arthritis (CAIA) in IFN-γ knockout mice, highlighting its therapeutic potential. Conclusion: TAK1 inhibition restores p53 functions in JIASFs and downregulates synovial inflammation, which warrants further studies that target TAK1 to treat JIA.
- Open Access
- 25 December 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 734-742
Diagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants
Objective: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 activity. Methods: Data were collected from individuals who underwent ADA2 testing from 2018 to 2025. Plasma ADA2 activity was determined using an established spectrophotometric assay. ADA2 variants were analyzed in transfected cells by enzyme assay and western blotting. Results: We determined that plasma ADA2 activity is 99.0% and 96.0% sensitive and 99.7% and 98.8% specific in distinguishing genetically confirmed DADA2 cases from controls and carriers, respectively. Eighteen individuals with DADA2 (9%) possessed detectable ADA2 activity, including several cases with levels seen in carriers. Residual ADA2 activity was associated with the vasculitis/inflammatory phenotype but not with disease severity. Genotype analysis revealed that 14 of 18 cases with residual plasma activity possessed at least one hypomorphic missense variant with greater than 20% residual ADA2 function when overexpressed in 293T cells, often occurring in trans with a more deleterious variant. In vitro analysis revealed that missense ADA2 variants exert variable dominant‐negative effects by forming large intracellular protein aggregates via disulfide bond formation at a cysteine residue (Cys408). Conclusion: We confirmed the utility of plasma ADA2 activity as a diagnostic assay and showed that the inflammatory phenotype of DADA2 occurred in cases with residual activity. In vitro findings illustrate potential interactions of ADA2 variants to synergistically disrupt protein function.
- 25 December 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 734-742
Open AccessDiagnostic Implications and Correlates of Plasma Adenosine Deaminase 2 Activity and ADA2 Variants
Objective: Deficiency of adenosine deaminase 2 (DADA2) is a monogenic autoinflammatory disease manifested as polyarteritis nodosa, stroke, and bone marrow failure. Leveraging an international cohort of 200 DADA2 cases, we aimed to characterize the diagnostic utility of a plasma ADA2 enzyme activity assay and understand the implications of residual ADA2 activity. Methods: Data were collected from individuals who underwent ADA2 testing from 2018 to 2025. Plasma ADA2 activity was determined using an established spectrophotometric assay. ADA2 variants were analyzed in transfected cells by enzyme assay and western blotting. Results: We determined that plasma ADA2 activity is 99.0% and 96.0% sensitive and 99.7% and 98.8% specific in distinguishing genetically confirmed DADA2 cases from controls and carriers, respectively. Eighteen individuals with DADA2 (9%) possessed detectable ADA2 activity, including several cases with levels seen in carriers. Residual ADA2 activity was associated with the vasculitis/inflammatory phenotype but not with disease severity. Genotype analysis revealed that 14 of 18 cases with residual plasma activity possessed at least one hypomorphic missense variant with greater than 20% residual ADA2 function when overexpressed in 293T cells, often occurring in trans with a more deleterious variant. In vitro analysis revealed that missense ADA2 variants exert variable dominant‐negative effects by forming large intracellular protein aggregates via disulfide bond formation at a cysteine residue (Cys408). Conclusion: We confirmed the utility of plasma ADA2 activity as a diagnostic assay and showed that the inflammatory phenotype of DADA2 occurred in cases with residual activity. In vitro findings illustrate potential interactions of ADA2 variants to synergistically disrupt protein function.
- 7 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (9)
Adipose tissue harbors pathogenic T cells in obesity that exacerbate inflammatory arthritis
Obesity worsens inflammatory arthritis severity, even in non-load–bearing joints, but the mechanism is unknown. Here, we show that there is an immunological mechanism mediated by T cells in adipose tissue. Using an antigen-induced arthritis model with trackable, arthritis-inducing CD8+ OT-I T cells, we found that OT-I T cells home to visceral adipose tissue (VAT) and expand there in the obese high-fat diet (HFD) context. Transplant of VAT from arthritic mice increased arthritis severity in naïve recipient mice and was ameliorated by CD8 T cell depletion. Bulk RNA sequencing identified pro-inflammatory changes to OT-I T cells in VAT characterized by increased IFN α and γ signaling after HFD. Intraperitoneal injection of IFNα, but not IFNγ, expanded CD8 T cell numbers in VAT. HFD-induced expansion of VAT CD8 T cells was ameliorated with global Ifnar1 deletion, and importantly, genetic deletion of Ifnar1 in T cells decreased arthritis severity in obese mice. These results provide a mechanistic explanation of how obesity worsens autoimmunity.
- 7 July 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (9)
Adipose tissue harbors pathogenic T cells in obesity that exacerbate inflammatory arthritis
Obesity worsens inflammatory arthritis severity, even in non-load–bearing joints, but the mechanism is unknown. Here, we show that there is an immunological mechanism mediated by T cells in adipose tissue. Using an antigen-induced arthritis model with trackable, arthritis-inducing CD8+ OT-I T cells, we found that OT-I T cells home to visceral adipose tissue (VAT) and expand there in the obese high-fat diet (HFD) context. Transplant of VAT from arthritic mice increased arthritis severity in naïve recipient mice and was ameliorated by CD8 T cell depletion. Bulk RNA sequencing identified pro-inflammatory changes to OT-I T cells in VAT characterized by increased IFN α and γ signaling after HFD. Intraperitoneal injection of IFNα, but not IFNγ, expanded CD8 T cell numbers in VAT. HFD-induced expansion of VAT CD8 T cells was ameliorated with global Ifnar1 deletion, and importantly, genetic deletion of Ifnar1 in T cells decreased arthritis severity in obese mice. These results provide a mechanistic explanation of how obesity worsens autoimmunity.
- Open Access
A multi-omics resource of B cell activation reveals genetic mechanisms for immune-mediated diseases
Most genetic variants that confer risk of complex immune-mediated diseases (IMDs) affect gene regulation in specific cell types. Their target genes and focus cell types are often unknown, partially because some effects are hidden in untested cell states. B cells play central roles in IMDs, including autoimmune, allergic, infectious, and cancer-related diseases. Despite this established importance, B cell activation states are underrepresented in functional genomics studies. In this study, we obtained B cells from 26 healthy female donors and stimulated them in vitro with six activation conditions targeting key pathways: the B cell receptor (BCR), Toll-like receptor 7 (TLR7), TLR9, CD40, and a cocktail that promotes differentiation into double negative 2 (DN2) IgD - CD27 - CD11c + CD21 - B cells, a likely pathogenic subset implicated in autoimmunity and infection. We profiled up to 24 B cell activation states and up to 5 control conditions using RNA-seq, single-cell RNA-seq with surface protein markers (CITE-seq), and ATAC-seq. We characterize how IMD-associated genes respond to stimuli and group into distinct functional programs. High-depth RNA-seq data reveals widespread splicing effects during B cell activation. Using single-cell data, we describe stimulus-dependent B cell fates. Chromatin data reveal transcription factors likely involved in B cell activation, and activation-dependent open chromatin regions that are enriched in IMD genetic risk. We experimentally validate a lupus risk variant in a stimulus-specific open chromatin region that regulates TNFSF4 expression, highlighting the relevance of studying B cell activation to elucidate disease association. These data are shared via an interactive browser that can be used to query the dynamics of gene regulation and B cell differentiation during activation by different stimuli, enhancing further investigation of B cells and their role in IMDs: https://mgalab.shinyapps.io/bcellactivation .
Open AccessA multi-omics resource of B cell activation reveals genetic mechanisms for immune-mediated diseases
Most genetic variants that confer risk of complex immune-mediated diseases (IMDs) affect gene regulation in specific cell types. Their target genes and focus cell types are often unknown, partially because some effects are hidden in untested cell states. B cells play central roles in IMDs, including autoimmune, allergic, infectious, and cancer-related diseases. Despite this established importance, B cell activation states are underrepresented in functional genomics studies. In this study, we obtained B cells from 26 healthy female donors and stimulated them in vitro with six activation conditions targeting key pathways: the B cell receptor (BCR), Toll-like receptor 7 (TLR7), TLR9, CD40, and a cocktail that promotes differentiation into double negative 2 (DN2) IgD - CD27 - CD11c + CD21 - B cells, a likely pathogenic subset implicated in autoimmunity and infection. We profiled up to 24 B cell activation states and up to 5 control conditions using RNA-seq, single-cell RNA-seq with surface protein markers (CITE-seq), and ATAC-seq. We characterize how IMD-associated genes respond to stimuli and group into distinct functional programs. High-depth RNA-seq data reveals widespread splicing effects during B cell activation. Using single-cell data, we describe stimulus-dependent B cell fates. Chromatin data reveal transcription factors likely involved in B cell activation, and activation-dependent open chromatin regions that are enriched in IMD genetic risk. We experimentally validate a lupus risk variant in a stimulus-specific open chromatin region that regulates TNFSF4 expression, highlighting the relevance of studying B cell activation to elucidate disease association. These data are shared via an interactive browser that can be used to query the dynamics of gene regulation and B cell differentiation during activation by different stimuli, enhancing further investigation of B cells and their role in IMDs: https://mgalab.shinyapps.io/bcellactivation .